2025-09-02 18:29:53,215 [INFO] numexpr.utils: Note: NumExpr detected 64 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 16.
2025-09-02 18:29:53,215 [INFO] numexpr.utils: NumExpr defaulting to 16 threads.
2025-09-02 18:29:54,572 [INFO] Investimate: Starting program
2025-09-02 18:29:55,845 [INFO] accelerate.utils.modeling: We will use 90% of the memory on device 0 for storing the model, and 10% for the buffer to avoid OOM. You can set `max_memory` in to a higher value to use more memory (at your own risk).
CUDA version: 12.4
GPU Name: NVIDIA A2
Inputs: tensor([[   1, 2378,  368,  506,  727]], device='cuda:0')
Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]Loading checkpoint shards:  50%|█████     | 1/2 [00:07<00:07,  7.27s/it]Loading checkpoint shards: 100%|██████████| 2/2 [00:10<00:00,  4.84s/it]Loading checkpoint shards: 100%|██████████| 2/2 [00:10<00:00,  5.20s/it]
Device set to use cuda:0
Setting `pad_token_id` to `eos_token_id`:2 for open-end generation.
Setting `pad_token_id` to `eos_token_id`:2 for open-end generation.

=============working===========

Final State:
{'question': 'Which sector is doing better in 2025 – pharma or IT?', 'answer': 'based on the given information, it appears that the pharmaceutical sector is performing better in 2025 than the it sector. the pharmaceutical sector has shown consistent earnings growth, resilience in macro downturns, and favorable policy tailwinds. on the other hand, the it sector is under pressure, facing mixed signals with slowing discretionary spending and macroeconomic headwinds.', 'context': 'and regulatory ease, strengthening prospects in UK/an OECD markets The Economic \n                        Times+1The Economic Times+1.\n                        • Dr. Reddy’s posted record quarterly revenue in Q1\u2009FY26 (+11%) and proﬁt rose modestly \n                        ~2%, with strong momentum in European generics (up 142%) Wikipedia+15Reuters+15The \n                        Times of India+15.\n                        Overall, pharma continues to demonstrate consistent earnings growth, resilience in macro \n                        downturns, and favorable policy tailwinds.\n                        IT Sector: Under Pressure, Mixed Signals \n                        • The Nifty IT index is down ~14% year-to-date in 2025, making it the worst-performing \n                        sector so far. Large-cap IT names like TCS, Infosys, and HCL have dropped sharply—TCS \n                        down ~21%, trading ~30% below its 52-week high India Infoline+1The Economic Times+1.\n                        • Earnings are being squeezed by slowing discretionary spending, macroeconomic headwinds,\n\n                        Pharmaceutical Sector: Strong and Resilient \n                        • The Nifty Pharma index rose ~11.5% between July 2024 and June 2025, notably beating \n                        the Nifty\u200950 (~5.7%) and most other major sectors \n                        PwC+15indiamacroindicators.co.in+15The Times of India+15.\n                        • Monthly growth in April 2025 was 7.8% YoY in pharma sales (₹19,711 crore), \n                        underscoring healthy demand and solid pricing dynamics The Times of India.\n                        • The broader pharmaceutical market grew ~8.4% in FY24-25, driven by chronic therapy \n                        demand domestically and strong exports from generic makers like Sun Pharma, Cipla, and \n                        Dr\u2009Reddy’s Jainam Broking Ltd+14Business Standard+14Reuters+14.\n                        • The India-UK free trade agreement is likely to boost pharma exports through tariff relief \n                        and regulatory ease, strengthening prospects in UK/an OECD markets The Economic \n                        Times+1The Economic Times+1.\n\n                        Key Sector Stats\n                        Metric Pharma IT\n                        Index Performance \n                        (1\u2009yr) 11.5% –14% (Nifty IT YTD)\n                        Sales Growth FY25 ~8–8.4% ~3–5%\n                        Earnings Trend Positive, steady Weak, margin pressure\n                        Export Momentum Rising (US, UK futures) Mixed – some growth, some headwinds\n                        Outlook Stable growth + \n                        tailwinds\n                        Under stress; cautious medium-term \n                        outlook\n                        ', 'summary': '', 'pointers': '1. Market Indices Performance.\n2. Societal Impact - Impact on Quality of Life/Solving Global Challenges.\n3. Financial Performance - Revenue Growth Rate (Year-over-Year), Profit Margins (Gross, Operating, Net), Market Capitalization Growth, R&D Spending as a Percentage of Revenue, Return on Investment (ROI).'}

Generated Answer:
based on the given information, it appears that the pharmaceutical sector is performing better in 2025 than the it sector. the pharmaceutical sector has shown consistent earnings growth, resilience in macro downturns, and favorable policy tailwinds. on the other hand, the it sector is under pressure, facing mixed signals with slowing discretionary spending and macroeconomic headwinds.
normal answer=========== Which sector is doing better in 2025 – pharma or IT?
A: Pharma
